Skip to search formSkip to main contentSkip to account menu

terbogrel

Known as: (E)-6-(3-(((Cyanoamino)((1,1- dimethylethyl)amino)methylene)amino)phenyl)-6-(3-pyridinyl)-5-hexenoic acid, 6-(3-(((Cyanoamino)((1,1-dimethylethyl)amino)methylene)amino)phenyl)-6-(3-pyridinyl)Hexenoic Acid, BIBV 308 SE 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
BACKGROUND Insufficient platelet inhibition is associated with an increased cardiovascular risk in up to 30% of patients taking… 
2005
2005
The pulmonary vasoconstrictor, thromboxane, may contribute to the development of pulmonary hypertension. Our objective was to… 
2004
2004
AIMS To characterize the pharmacokinetics of terbogrel, a new combined thromboxane A2 (TxA2) receptor and synthase inhibitor, in… 
Highly Cited
2003
Highly Cited
2003
Background—Aspirin inhibits platelet activation and reduces atherothrombotic complications in patients at risk of myocardial… 
Highly Cited
2002
Highly Cited
2002
BACKGROUND Circulating mediators, including thromboxane A2, the vasoconstrictor, platelet aggregant, and smooth muscle mitogen… 
Review
2002
Review
2002
Past medical therapy for pulmonary arterial hypertension included the use of calcium-channel antagonists in acute vasoreactive… 
Review
2002
Review
2002
Until a few years ago, "conventional" treatment for pulmonary arterial hypertension (PAH) included oral anticoagulants, calcium… 
2000
2000
Terbogrel, (E)-6-[4-(3-tert-butyl-2-cyanoguanidino)phenyl]-6-(3-pyridyl)hex-5 -enoic acid, C(23)H(27)N(5)O(2), a mixed… 
1999
1999
A new series of omega-disubstituted alkenoic acid derivatives derived from samixogrel 5 were designed and synthesized as combined…